Format

Send to

Choose Destination
Sci Transl Med. 2010 Sep 8;2(48):48ps45. doi: 10.1126/scitranslmed.3001251.

Targeting a common collaborator in cancer development.

Author information

1
Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. apmyers@partners.org

Abstract

In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.

PMID:
20826838
PMCID:
PMC3425950
DOI:
10.1126/scitranslmed.3001251
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center